Abstract
Lipoprotein glomerulopathy (LPG) is a rare hereditary disease characterized by the accumulation of much thrombi material consisting of lipoproteins at the glomerular capillary lumen. Most patients show nephrotic syndrome; nearly half progress to chronic renal failure. Intensive therapy with lipid-lowering agents reportedly engenders clinical remission with histological resolution. We report the case of a 14-year-old Japanese female patient who had been in a nephrotic condition with hematuria from 4 years old and who had been diagnosed based on pathological and molecular examination at 7 years old. We initially treated the patient with probucol, enalapril (angiotensin-converting enzyme inhibitor: ACEI), and dipyridamole from age 7, but achieved no improvement in her nephrotic status. Subsequently, we replaced probucol with bezafibrate at age 11 and added atorvastatin calcium hydrate and valsartan (angiotensin II receptor blocker: ARB) the following year. The next 3 years’ treatment improved her nephrotic status, decreased serum apolipoprotein E, and markedly decreased intraglomerular lipoprotein thrombi. Early and intensive therapy with antilipidemic drugs combined with ACEI and ARB is inferred to be effective for LPG.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13:148–53.
Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, et al. Apoprotein E Sendai (arginine145proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8:820–3.
Kamata M, Shimizu K, Aikawa I. A case showing specific histology with lipid deposition, developing into renal failure and receiving renal transplantation. Jpn J Nephrol. 1989;31:1258.
Foster K, Matsunaga A, Matalon R, Saito T, Gallo G, D’Agati V, et al. A rare case of posttransplantation nephrotic syndrome. Am J Kidney Dis. 2005;45:1132–8.
Andrews PA, O’Donnell PJ, Dilly SA, Snowden SA, Bewick M. Recurrence of lipoprotein glomerulopathy after renal transplantation. Nephrol Dial Transplant. 1997;12:2442–4.
Mourad G, Djamali A, Turc-Baron C, Cristol JP. Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Nephrol Dial Transplant. 1998;13:1292–4.
Miyata T, Sugiyama S, Nangaku M, Suzuki D, Uragami K, Inagi R, et al. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol. 1999;10:1590–5.
Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis. 2003;41:244–9.
Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis. 2003;169:293–9.
Amenomori M, Haneda M, Morikawa J, Nishigaki I, Maeda S, Hidaka H, et al. A case of lipoprotein glomerulopathy successfully treated with probucol. Nephron. 1994;67:109–13.
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet. 2003;361:117–24.
Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18–25.
Catapano F, Chiodini P, Nicola LD, Minutolo R, Zamboli P, Gallo C, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis. 2008;52:475–85.
Matsunaga A, Numakura C, Kanno M, Yoshimura Y, Hayasaka K. A case with lipoprotein glomerulopathy. J Jpn Pediatr Soc. 2002;106:500–3. (Japanese).
Saito T, Ishigaki Y, Oikawa S, Yamamoto T. Role of apolipoprotein E variants in lipoprotein glomerulopathy and other renal lipidoses. Clin Exp Nephrol. 2001;5:201–8.
Saito T, Oikawa s, Sato H, Sasaki J. Lipoprotein glomerulopathy: renal Lipidosis induced by novel apolipoprotein E varians. Nephron. 1999;83:193–201.
Saito T, Sato H, Oikawa S. Lipoprotein glomerulopathy: a new aspect of lipid induced glomerular injury. Nephrology. 1995;1:17–24.
Zhang P, Matalon R, Kaplan L, Kumar A, Gallo G. Lipoprotein glomerulopathy: first report in a Chinese male. Am J Kidney Dis. 1994;24:942–50.
Watanabe Y, Ozaki I, Yoshida F, Fukatsu A, Itoh Y, Matsuo S, et al. A case of nephrotic syndrome with glomerular lipoprotein deposition with capillary ballooning and mesangiolysis. Nephron. 1989;51:265–70.
Maruyama K, Arai H, Ogawa T, Tomizawa S, Morikawa A. Lipoprotein glomerulopathy: a pediatric case report. Pediatr Nephrol. 1997;11:213–4.
Hagiwara M, Yamagata K, Matsunaga T, Arakawa Y, Usui J, Shimizu Y, et al. A novel apolipoprotein E mutation, ApoE tukuba (Arg 144Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23:381–4.
Kinomura M, Sugiyama H, Saito T, Matsunaga A, Sada K, Kanzaki M, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23:751–6.
Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Matsunaga, A., Furuyama, M., Hashimoto, T. et al. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol 13, 659–662 (2009). https://doi.org/10.1007/s10157-009-0207-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-009-0207-1